Synaffix to provide access to proprietary antibody-drug conjugate (ADC) technologies Genmab secures rights for conducting research on ADCs against multiple drug targets with options for exclusive worldwide development and commercialization of resulting therapies Synaffix to receive an upfront payment of USD $4.5 million with a total deal value of up to USD $415 million plus […]